The Department of Justice has announced it is formally withdrawing 54 regulatory actions, including several tied to the Drug Enforcement Administration and Bureau of Prisons, as part of the Trump administration’s deregulatory push.

According to a notice scheduled for publication in the Federal Register on September 11, the DOJ is ending 16 proposed rules that had already appeared in the Federal Register, along with 38 additional actions that were listed in the Unified Agenda but never advanced.

The decision follows President Donald Trump’s January 31 executive order, “Unleashing Prosperity Through Deregulation,” which requires federal agencies to ensure the overall cost of new regulations is “significantly less than zero” and to offset new regulatory costs by repealing at least ten existing rules.

Among the withdrawals are DEA proposals on telepharmacy practice, disposal methods for controlled substances, and exempted prescription products. The agency also dropped planned rulemakings related to analytical labs and hemp, as well as a proposed expansion of medical marijuana and cannabidiol research.

Other withdrawals cover Bureau of Prisons rules on compassionate release, inmate financial responsibility, and infectious disease testing, as well as ATF proposals redefining certain firearms classifications.

Attorney General Pamela Bondi signed the notice on September 8, stating that the DOJ identified these actions as no longer aligning with current agency needs and priorities. Importantly, the withdrawal does not affect the separate ongoing process to reschedule marijuana under the Controlled Substances Act, which remains active.